评估 miR-331-3p 和 miR-23b-3p 作为早期丙型肝炎病毒相关肝细胞癌的血清生物标志物。
Evaluation of miR-331-3p and miR-23b-3p as serum biomarkers for hepatitis c virus-related hepatocellular carcinoma at early stage.
机构信息
Department of Clinical Laboratory, Affiliated Hospital of Chengde Medical University, 36, Nanyingzi Road, Chengde, 067000, PR China.
Department of Hepatobiliary Surgery, Affiliated Hospital of Chengde Medical University, 36, Nanyingzi Road, Chengde, 067000, PR China.
出版信息
Clin Res Hepatol Gastroenterol. 2020 Feb;44(1):21-28. doi: 10.1016/j.clinre.2019.03.011. Epub 2019 Apr 30.
BACKGROUND AND AIMS
This study aimed to investigate the diagnostic values of serum miR-331-3p and miR-23b-3p as tumor markers for the diagnosis of hepatocellular carcinoma (HCC) at early stage.
METHODS
A total of 191 subjects were enrolled and consisted of 45 healthy controls (HC), 106 hepatitis c virus (HCV)-related chronic liver disease (CLD) patients, and 40 early-stage HCC patients. CLD patients were subdivided according to Metavir fibrosis-scoring. Serum miR-331-3p and miR-23b-3p were measured. The area under curves (AUC) was calculated for each microRNA and compared with that for alpha-fetoprotein (AFP) in the detection of HCC at early stage.
RESULTS
Serum miR-331-3p was significantly higher in early-stage HCC than that in CLD and HC respectively, and it decreased significantly after surgery in early-stage HCC. Contrarily, serum miR-23b-3p was significantly lower in early-stage HCC and increased significantly after surgery. Further, receiver operating characteristic analysis demonstrated AUC was 0.806 (95%CI: 0.728-0.883; sensitivity: 85.85%, specificity: 65.00%) for serum miR-23b-3p in discriminating early-stage HCC from CLD patients, higher than that for AFP (AUC:0.660, 95%CI: 0.556-0.764; sensitivity: 70.00%, specificity: 56.60%). In discrimination early-stage HCC from severe fibrosis/cirrhosis (F3 + F4) patients, both miR-23b-3p (AUC: 0.796, 95%CI: 0.703-0.889; sensitivity: 85.11%, specificity: 65.00%) and miR-331-3p (AUC:0.832, 95%CI: 0.812-0.953; sensitivity: 75.00%, specificity: 85.11%) had better diagnostic performances than AFP (AUC:0.632, 95%CI: 0.512-0.753; sensitivity: 50.00%, specificity: 55.32%). Serum miR-331-3p levels also showed a significant correlation with BCLC stages of HCC.
CONCLUSION
Serum miR-331-3p and miR-23b-3p could be used as novel invasive biomarkers in the early detection of HCC in high-risk patients.
背景与目的
本研究旨在探讨血清 miR-331-3p 和 miR-23b-3p 作为肿瘤标志物在早期诊断肝细胞癌 (HCC) 中的诊断价值。
方法
共纳入 191 例受试者，包括 45 例健康对照者 (HC)、106 例丙型肝炎病毒 (HCV) 相关慢性肝病 (CLD) 患者和 40 例早期 HCC 患者。根据 Metavir 纤维化评分，CLD 患者进一步分为亚组。检测血清 miR-331-3p 和 miR-23b-3p。计算每个 miRNA 的曲线下面积 (AUC)，并与早期 HCC 中甲胎蛋白 (AFP) 的检测进行比较。
结果
早期 HCC 患者血清 miR-331-3p 明显高于 CLD 和 HC 患者，且早期 HCC 患者手术后血清 miR-331-3p 明显降低。相反，早期 HCC 患者血清 miR-23b-3p 明显降低，手术后明显升高。进一步的受试者工作特征分析表明，血清 miR-23b-3p 区分早期 HCC 与 CLD 患者的 AUC 为 0.806(95%CI：0.728-0.883；敏感性：85.85%，特异性：65.00%)，高于 AFP(AUC：0.660，95%CI：0.556-0.764；敏感性：70.00%，特异性：56.60%)。在区分早期 HCC 与严重纤维化/肝硬化 (F3+F4) 患者时，miR-23b-3p(AUC：0.796，95%CI：0.703-0.889；敏感性：85.11%，特异性：65.00%)和 miR-331-3p(AUC：0.832，95%CI：0.812-0.953；敏感性：75.00%，特异性：85.11%)的诊断性能均优于 AFP(AUC：0.632，95%CI：0.512-0.753；敏感性：50.00%，特异性：55.32%)。血清 miR-331-3p 水平也与 HCC 的巴塞罗那临床肝癌 (BCLC) 分期呈显著相关性。
结论
血清 miR-331-3p 和 miR-23b-3p 可作为高危患者 HCC 早期检测的新型侵袭性生物标志物。
Zotero 插件